	Application No.	Applicant(s)
Notice of Allowability	10/649,130	KLYOSOV ET AL.
	Examiner	Art Unit
	Traviss C. McIntosh	1623
The MAILING DATE of this communication ap All claims being allowable, PROSECUTION ON THE MERITS herewith (or previously mailed), a Notice of Allowance (PTOL-8 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.3	IS (OR REMAINS) CLOSED in t 35) or other appropriate commun RIGHTS. This application is sul 13 and MPEP 1308.	his application. If not included ication will be mailed in due course. THIS
1. This communication is responsive to <u>amendment filed 1/</u>	<u>/6/05</u> .	
2. The allowed claim(s) is/are <u>1-10</u> .		
3. The drawings filed on are accepted by the Exami	ner.	
 4. Acknowledgment is made of a claim for foreign priority a) All b) Some* c) None of the: 1. Certified copies of the priority documents hat 2. Certified copies of the priority documents hat 3. Copies of the certified copies of the priority of International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	ive been received.	No
Applicant has THREE MONTHS FROM THE "MAILING DATE noted below. Failure to timely comply will result in ABANDON THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		reply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be sub INFORMAL PATENT APPLICATION (PTO-152) which g		
6. CORRECTED DRAWINGS (as "replacement sheets") m	ust be submitted.	
(a) \square including changes required by the Notice of Draftspe	erson's Patent Drawing Review (PTO-948) attached
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examine Paper No./Mail Date	er's Amendment / Comment or in	the Office action of
Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in	1.84(c)) should be written on the	drawings in the front (not the back) of
DEPOSIT OF and/or INFORMATION about the department attached Examiner's comment regarding REQUIREMEN	posit of BIOLOGICAL MATER	RIAL must be submitted. Note the
Attachment(s)	- -	
 Notice of References Cited (PTO-892) D Notice of Draftperson's Patent Drawing Review (PTO-948) 	<u> </u>	mal Patent Application (PTO-152)
,	Paper No./M	 Interview Summary (PTO-413), Paper No./Mail Date Examiner's Amendment/Comment
 Information Disclosure Statements (PTO-1449 or PTO/SE Paper No./Mail Date 	_	
Examiner's Comment Regarding Requirement for Deposit Of Pictorial Metarial		atement of Reasons for Allowance JAMES 0. WILSON
of Biological Material	9.	SUPERVISORY PATENT EXAMINER TECHNOLOGY GENTER 1600

Notice of Allowability

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04)

Art Unit: 1623

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

The first paragraph on page 1 under the heading "Related Applications" has been deleted and replaced with the following new paragraph:

This Divisional application claims priority to and the benefit of US Patent Application serial number 09/818,596, filed March 27, 2001, now US Patent 6,645,946.

Terminal Disclaimer

The terminal disclaimer filed on 1/6/2005 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of application serial number 10/108,237 has been reviewed and is accepted. The terminal disclaimer has been recorded.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: claims 1-10 are allowed due to applicants filing of the three terminal disclaimers combined with the fact the art does not teach or fairly suggest compositions comprising a chemotherapeutic agent and

Art Unit: 1623

galactomannan in a mixture, wherein the closest prior art is seen to be Ouchi et al. (JMS Pure Applied Chem., A34(6), 1997, pp. 975-989, cited on IDS mailed 10/4/04) who teaches conjugates of a dicarboxylated ring-opened derivative of galactomannan (see scheme 1 compound vs. compound of figure 1 in Ouchi et al.) and Adriamycin which are covalently linked to each other.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Traviss C. McIntosh whose telephone number is 571-272-0657. The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/649,130

Art Unit: 1623

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Traviss C. McIntosh III March 16, 2005 James O. Wilson

Supervisory Patent Examiner

Page 4

Art Unit 1623